| Therapeutic | Fresolimumab |
| Target | TGFB |
| Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS |
| Light Chain | ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK |
| 100% seqID Fv Structure | 3eo0 [Fvs: BA, DC], 3eo1 [Fvs: BA, ED, HG, KJ], 4kv5 [Fvs: EF, GK, HL, JI], 4kxz [Fvs: HL, JI, NM, QP] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3eo0 [Fvs: BA, DC] |
| 100% seqID Structure | 4kxz [Fvs: HL, JI, NM, QP] |
| 100% seqID Structure | 4kv5 [Fvs: EF, GK, HL, JI] |
| 100% seqID Structure | 3eo1 [Fvs: BA, ED, HG, KJ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Phase-I |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | CAT Phage Display |
| INN Year Proposed | 2009 |
| INN Year Recommended | 2010 |
| Companies Involved | Cambridge Antibody Technology, Baylor College of Medicine, Genzyme Corporation, Sanofi Genzyme |
| Conditions Approved | na |
| Conditions Active | Osteogenesis imperfecta |
| Conditions Discontinued | Fibrosis, Malignant melanoma, Pulmonary fibrosis, Renal cancer, Focal segmental glomerulosclerosis |
| Notes | na |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
